Update on sirolimus drug-eluting stents

Current Pharmaceutical Design

Volumn 10, Issue 4, 2004, Pages 337-348

  Kipshidze, Nicholas ^a   Leon, Martin B ^a   Tsapenko, Mykola ^a   Falotico, Robert ^b   Kopia, Gregory A ^b   Moses, Jeffrey ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; CLOPIDOGREL; COPOLYMER; CYTOSINE DEAMINASE; DACTINOMYCIN; GANCICLOVIR; KALLIKREIN; MACROGOL; METAL; MYC PROTEIN; NITRIC OXIDE SYNTHASE; PACLITAXEL; POLY(3 HYDROXYBUTYRIC ACID); POLY(ORTHO ESTER); POLYESTER; POLYETHYLENE TEREPHTHALATE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYMER; POLYOLEFIN; POLYURETHAN; PROTEIN TYROSINE KINASE; RAPAMYCIN; SILICONE; TISSUE FACTOR PATHWAY INHIBITOR; VALERIC ACID;

AORTA BIFURCATION; ARTERY DYSPLASIA; ARTERY INTIMA PROLIFERATION; ARTERY WALL; BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; BLOOD VESSEL DIAMETER; BLOOD VESSEL OCCLUSION; BRACHYTHERAPY; CHRONIC INFLAMMATION; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST BENEFIT ANALYSIS; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; ELUTION; FOLLOW UP; GENE DELIVERY SYSTEM; HEART DISEASE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MATERIAL COATING; MECHANICAL STRESS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SIDE EFFECT; THICKNESS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VEIN GRAFT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CELL DIVISION; CLINICAL TRIALS; CORONARY RESTENOSIS; HUMANS; MUSCLE, SMOOTH, VASCULAR; SIROLIMUS; STENTS;

EID: 0742306379     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453315     Document Type: Review

References (92)

1. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998; 98: 1802-1820.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994, 331: 496-501.
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Eng J Med 1994, 331: 489-495.
4. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L, Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty N Engl J Med 1987, 316: 701-706.
5. Topol EJ. Coronary-artery stents - gauging, gorging, and gouging. N Engl J Med 1998, 339: 1702-1704.
6. Serruys PW, Foley DP, Suttorp MJ, Rensing BJ, Suryapranata H, Materne P, et al. A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions. JACC 2002; 39: 393-9.
7. van den Brand MJ, Rensing BJ, Morel MA, Foley DP, de Valk V, Breeman A, et al. The effect of completeness of revascularization on event-free survival at one-year in the ARTS trial. JACC 2002; 39: 559-64.
8. El-Omar MM, Dangas G, Iakovou I, Mehran R. Update on In-stent Restenosis. Current Interventional Cardiology Reports 2001, 3: 296-305.
9. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. Circulation 1987; (3): 636-42.
10. Wilensky RL, March KL, Gradus-Pizlo I, Sandusky G, Fineberg N, Hathaway DR. Vascular Injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. Circulation 1995; 92(10): 2995-3005.
11. Stoltenberg RL, Geraghty J, Steele DM, Kennedy E, Hullett DA, Sollinger HW. Inhibition of intimal hyperplasia in rat aortic allografts with cyclosporine. Transplantation 1995; 60(9): 993-8.
12. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 1994; 89: 2888-2891.
13. Schwartz R, Holmes D, Topol E. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1284-1293.
14. Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990; 82: 2190-2200.
15. Ross R, Wight TN, Strandness E, Thiele B. Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol 1984; 114: 79-93.
16. Mosse PR, Campbell GR, Campbell JH. Smooth muscle phenotypic expression in human carotid arteries. Lab Invest 1985; 53: 556-562.
17. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369-375.
18. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. Lab Invest 1983; 49: 327-333.
19. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for atherosclerosis and restenosis. Circulation Res 1995; 77: 445-465.
20. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating -cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993; 90: 8474-8478.
21. Sirois MG, Simons M, Edelman BR. Platelet release of platelet derived growth factor is required for intimal hyperplasia in rate vascular injury model. Circulation 1994; 90(Suppl. 1): I-511; 2751.
22. Mintz GS, Popma JJ, Hong MK, Pichard AD, Kent KM, Satter LF, et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996, 78: 18-22.
23. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998, 81: 4E-6E.
24. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98: 224-233.
25. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
26. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89: 507-511.
27. Sriram V, Patterson C. Cell cycle in vasculoproliferative diseases-potential interventions and routes of delivery. Circulation 2001; 103:2414-2419.
28. Koster R, Vieluf D, Kiehn M, Sommerauer M, Kahler J, Baldus S, et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 2000; 356: 1895-1897.
29. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic pattern of in-stent restenosis: Classification and implication for long term outcome. Circulation 1999; 100: 1872-8
30. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, et al. Local Paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000; 35(7): 1969-76.
31. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological Predictors of Restenosis After Coronary Stenting in Humans. Circulation 2002; 105: 2974-80
32. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52
33. Buchwald AB, Wagner AH, Webel C, Hecker M. Decoy Oligodeoxynucleotide Against Activator Protein-1 Reduces Neointimal Proliferation After Coronary Angioplasty in Hypercholesteromic Minipigs. J Am Coll Card, 2002; 39(4): 732-8
34. Kipshidze N, Moses J, Shankar LR, Leon M. Perspectives on antisense therapy for the prevention of restenosis. Current Opinions in Molecular Therapeutic 2001; 3(3): 265-277.
35. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697-1703.
36. Malhotra S, Teirstein PS. The SCRIPPS trial -catheter-based radiotherapy to inhibit coronary restenosis. J Invasive Cardiol 2000; 12(6): 330-32.
37. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344(4): 250-6.
38. Teirstein PS, Kuntz RE. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. Circulation 2001 Nov. 20; 104(21): 2620-6.
39. George SJ, Angelini GD, Capogrossi MC, Baker AH. Wild-tipe p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Therapy 2001; 8: 668-76
40. Murakami H, Yayama K, Miao RQ, Wang C, Chao L, Chao J. Kallikrein Gene Delivery Inhibits Vascular Smooth Muscle Cell Growth and Neointima Formation in the Rat Artery After Ballon Angioplasty. Hypertension 1999; 34: 164-170
41. Steg PG, Tahlil O, Aubailly N, Caillaud JM, Dedieu JF, Berthelot K, et al. Reduction of Restenosis After Angioplasty in an Atheromatous Rabbit Model by Suicide Gene Therapy. Circulation 1997; 96: 408-411
42. Harrell RL, Rajanayagam S, Doanes AM, Guzman RJ, Hirschowitz EA, Crystal RG, et al. Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Accumulation by Adenovirus-Mediated Gene Transfer of Cytosine Deaminase. Circulation 1997; 96(2): 621-7
43. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT. Thromboresistence of Balloon-Injured Porcine Carotid Arteries After Local Gene Transfer of Human Tissue Factor Pathway Inhibitor. Circulation 2000; 101(3): 289-95
44. Van Belle E, Tio FO, Chen D, Maillard L, Chen D, Kearney M, et al. Passivation of Metalic Stents After Arterial Gene Transfer of phVEGF 165 Inhibits Thrombus Formation and Intimal Thickening. J Am Coll Cardiol 1997; 29: 1371-9
45. Yoon JH, Wu CJ, Homme J, Tuch RJ, Wolff RG, Topol EJ, et al. Local Delivery of Nitric Oxide from an Eluting Stent to Inhibit Neointimal Thickening in a Porcine Coronary Injury Model. Yonsei Med J 2002; 43(2): 242-251
46. Feldman MD, Sun B, Koci BJ, Wu CC, Kneller JR, Borovetz HS, et al. Stent-Based Gene Therapy. J long term Eff Med Implants 2000; 10: 47-68
47. Bailey S. Local drug delivery during percutaneous coronary intervention. Curr Interv Cardiol Rep 2000; 2(4): 349-357.
48. Oberhoff M, Herdeg C, Al Ghobainy R, Cetin S, Kutter A, Horch B, et al. Local delivery of Paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv 2001; 53(4): 562-8.
49. Ettenson DS, Edelman ER. Local drug delivery: an emerging approach in the treatment of restenosis. Vasc Med 2000; 5(2): 97-102.
50. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99(16): 2164-2170.
51. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, et al. Stent-based delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model. Circulation 2001; 104: 1188-1193.
52. Marx SO, Marks AR. Bench to Bedside: The Development of Rapamycin and its application to stent restenosis. Circulation 2001; 104: 852-855.
53. Marx SO, Jayaraman T, Go LO, Marks, AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76: 412-417.
54. Mohacsi PJ, Tüller D, Hulliger B, Wijngaard, PLJ. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transp 1997; 16: 484-492.
55. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996; 98: 2277-2283.
56. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 1993; 55: 1409-1418.
57. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655-661.
58. Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, Morris RE, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 1999; 100: 67-74.
59. Hofman SH, van Beusekom HM, Serruys PW, van Der Giessen WJ. Recent developments in coated stents. Curr Interv Cardiol 2001; 3(1): 2836.
60. Klugherz BD, Llanos G, Lieuallen W, Kopia G, Papandreou G, Narayanan P, et al. Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent. Coronary Artery Disease 2002; 13(3): 183-188.
61. Carter AJ, Bailey LR, Llanos G, Lieuallen W, Kopia G, Papandreou G, et al. Stent based sirolimus delivery reduces neointimal proliferation in a porcine coronary model of restenosis. J Am Col Cardiol 2000; 35: 13A.
62. Kopia GA, Falotico R, Gallagher L, Siegel J, Carter A, Tio F, et al. Sirolimus-Eluting Stents: Regrowth of Endothelial Cells Following Stent Implantation. Am J Cardiol 2002; 90(Suppl 6A): 113H.
63. Kopia GA, Snead D, Falotico R, Lauer M, Fischell T, Devries J, et al. Pharmacokinetics and Pharmacodynamics of Sirolimus-Eluting Stents. Am J Cardiol 2002; 90(Suppl 6A): 115H.
64. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D, Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3(3): 324-7.
65. Saikali JA, Truong LD, Suki WN. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003; 3(2): 229-30
66. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, et al. Lack of neointimal proliferation after implantation of Sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular study. Circulation 2001; 103 92) 192-195.
67. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting stents. Circulation 2001; 104(17): 2007-11.
68. Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, et al. Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries. Circulation 2003; 107: 381-3
69. Tanabe K, Degertekin M, Regar E, Ligthart JM, van der Giessen WJ, Serruys PW. No delayed restenosis at 18 months after implantation of sirolimus-eluting stent. Catheter Cardiovasc Interv 2002 57(1): 65-8.
70. Guagliumi G, Farb A, Musemeci G, Valsecchi O, Tespili M, Motta T, et al. Sirolimus-Eluting Stent Implanted in Human Coronary Artery for 16 Months. Circulation 2003; 107(9): 1340-1
71. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346(23): 1773-80.
72. Abizaid A, Serruys P, Abizaid A, Sousa JE, Costa MA. The absence of edge effect after implantation of sirolimus-eluting stents to treat in-stent restenosis: a three-dimensional intravascular ultrasound volumetric analysis [abstract]. JACC 51st Annual Scientific Session, Atlanta, GA, March 17-20, 2002; 19: 5(Suppl A) 58A: 1174-14.
73. Degertekin M, Tanabe E, Regar J, Sousa JE, Colombo A, Guagliumi G, et al. Are sirolimus-eluting stents inducing vascular remodeling? A subgroup analysis of 3D-intravascular ultrasound in the RAVEL trial. JACC. 51 Annual Scientific Session, Atlanta, GA March 17-20, 2002; 5(Suppl A) 59A: 1174-18.
74. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, et al. RAVEL Study Group. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002; 106(7): 798-803.
75. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002; 106(13): 1610-3.
76. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, et al. RAVEL Study Group. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002; 106(15): 1949-56.
77. Tanabe K, Serruys PW, Degertekin M, Regar E, van Domburg RT, Sousa JE, et al. Fate of side branches after coronary arterial sirolimus-eluting stent implantation. Am J Cardiol 2002; 90(9): 937-41.
78. Moses JW, Leon MB, Popma JJ, Kuntz RE. The U.S. Multicenter, Randomized, Double-Blind Study of the Sirolimus-Eluting Stent in Coronary Lesions: Early (30-Day) Safety Results. Circulation 2001; 104:II-464; 2200.
79. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, Carlier SG, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. The first clinical experience. J Am Coll Cardiol 2003; 41(2): 184-9.
80. De Scheerder I, Yanming H, Dens J, Wang L, Desmet W. Treatment of in-Stent Restenosis Using Paclitaxel Eluting Stents: A Single Centre pilot Trial. Circulation 2001; 104; 17: II-742; 3503.
81. Liistro F, Colombo A. Late acute thrombosis after Paclitaxel eluting stent implantation. Heart 2001; 86(3): 262-4.
82. Degertekin M, Regar E, Tanabe K, Sousa JE, Colombo A, Guagliumi G, et al. Incidence of incomplete stent apposition at six-month follow-up in the multi center RAVEL trial. JACC. 51 Annual Scientific Session, Atlanta, GA March 17-20, 2002; 5(Suppl A) 38A: 823-5.
83. De la Fuente LM, Miano J, Mrad J, Penaloza E, Yeung AC, Eury R, et al. Initial results of the Quanam drug-eluting stent (QuaDS-QP-2). Registry (BARDDS) in human subjects. Catheter Cardiovasc Interv 2001; 53(4): 480-8.
84. Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003; 107(1): 24-7.
85. Crook MF, Newby AC, Southgate KM. Expression of intercellular adhesion molecules in human saphenous veins: effects of inflammatory of cytokines and neointima formation in culture. Atherosclerosis 2000; 150(1): 33-41.
86. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103(18): 2289-95.
87. Kipshidze N, Moses JW, Leon MB. Paclitaxel-coated stent: is there a light at the end of the tunnel? J Am Coll Cardiol 2001; 38(1): 292-3.
88. Chao-Wei H, Wu D, Edelman E. Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery. Circulation 2001; 104: 600-605.
89. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA. Drug-Eluting Stems in Preclinical Studies. Recommended Evaluation From a Consensus Group. Circulation 2002; 106: 1867-7304.
90. Bilfinger TV, Stefano GB. The role of protease inhibition with emphasis on the effects of inflammation and vascular immune phenomena. Curr Pharm Design 2002; 8(7): 505-9.
91. Blum JE, Handmaker H. Small peptide radiopharmaceuticals in the imaging of acute thrombus. Curr Pharm Design 2002; 8(20): 1815-26.
92. Elba S, Buongiorno GP, Caruso ML, Noviello MR, Manghisi OG. Main characteristics of hepatocellular carcinoma and cirrhosis and therapeutic approaches. Curr Pharm Design 2002; 8(11): 1007-11.